Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Drugs in R&D
|
March 18, 2011
Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study
Michael Lissy, Marité Ode, Karsten Roth
Human Resources for Health
|
November 21, 2025
Workplace violence and burnout among emergency medical service workers and nurses in Germany: a cross-sectional study
Karsten Roth, Julia Köppen, Cornelia Henschke
BMC Emergency Medicine
|
August 22, 2018
Burnout and safety outcomes - a cross-sectional nationwide survey of EMS-workers in Germany
Natalie Baier, Karsten Roth, Susanne Felgner, et al.
IEEE Transactions on Pattern Analysis and Machine Intelligence
|
August 6, 2020
Sharing Matters for Generalization in Deep Metric Learning
Timo Milbich, Karsten Roth, Biagio Brattoli, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))
|
December 10, 2020
[Association between Safety Culture and Risk of Burnout: A Survey of Non-Medical Rescue Workers]
Karsten Roth, Natalie Baier, Susanne Felgner, et al.
Clinical Nephrology
|
June 27, 2012
Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl
Walter H Hörl, Francesco Locatelli, Marianne Haag-Weber, et al.
Pharmacology Research & Perspectives
|
August 17, 2019
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg<sup>®</sup>, a pegfilgrastim biosimilar in healthy subjects
Karsten Roth, Dirk Lehnick, Hendrik Wessels, et al.
Pharmacology Research & Perspectives
|
August 17, 2019
Pharmacodynamics, safety, and immunogenicity of Pelmeg<sup>®</sup>, a pegfilgrastim biosimilar in healthy subjects
Hendrik Wessels, Dirk Lehnick, Josef Höfler, et al.
Clinical Nephrology
|
December 22, 2011
Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study
Marianne Haag-Weber, Kai-Uwe Eckardt, Walter H Hörl, et al.
JAMA Neurology
|
January 23, 2023
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial
Bernhard Hemmer, Heinz Wiendl, Karsten Roth, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Drugs in R&D
|
March 18, 2011
Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study
Michael Lissy, Marité Ode, Karsten Roth
Human Resources for Health
|
November 21, 2025
Workplace violence and burnout among emergency medical service workers and nurses in Germany: a cross-sectional study
Karsten Roth, Julia Köppen, Cornelia Henschke
BMC Emergency Medicine
|
August 22, 2018
Burnout and safety outcomes - a cross-sectional nationwide survey of EMS-workers in Germany
Natalie Baier, Karsten Roth, Susanne Felgner, et al.
IEEE Transactions on Pattern Analysis and Machine Intelligence
|
August 6, 2020
Sharing Matters for Generalization in Deep Metric Learning
Timo Milbich, Karsten Roth, Biagio Brattoli, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))
|
December 10, 2020
[Association between Safety Culture and Risk of Burnout: A Survey of Non-Medical Rescue Workers]
Karsten Roth, Natalie Baier, Susanne Felgner, et al.
Clinical Nephrology
|
June 27, 2012
Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl
Walter H Hörl, Francesco Locatelli, Marianne Haag-Weber, et al.
Pharmacology Research & Perspectives
|
August 17, 2019
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg<sup>®</sup>, a pegfilgrastim biosimilar in healthy subjects
Karsten Roth, Dirk Lehnick, Hendrik Wessels, et al.
Pharmacology Research & Perspectives
|
August 17, 2019
Pharmacodynamics, safety, and immunogenicity of Pelmeg<sup>®</sup>, a pegfilgrastim biosimilar in healthy subjects
Hendrik Wessels, Dirk Lehnick, Josef Höfler, et al.
Clinical Nephrology
|
December 22, 2011
Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study
Marianne Haag-Weber, Kai-Uwe Eckardt, Walter H Hörl, et al.
JAMA Neurology
|
January 23, 2023
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial
Bernhard Hemmer, Heinz Wiendl, Karsten Roth, et al.
Page
of 2